Xenetic Biosciences (XBIO) Competitors $3.11 -0.13 (-4.01%) Closing price 06/13/2025 03:39 PM EasternExtended Trading$3.04 -0.07 (-2.25%) As of 06/13/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIO vs. CING, HOOK, LGVN, LPCN, GOVX, LEXX, DRRX, LPTX, COCP, and PMNShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Cingulate (CING), Hookipa Pharma (HOOK), Longeveron (LGVN), Lipocine (LPCN), GeoVax Labs (GOVX), Lexaria Bioscience (LEXX), DURECT (DRRX), Leap Therapeutics (LPTX), Cocrystal Pharma (COCP), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical preparations" industry. Xenetic Biosciences vs. Its Competitors Cingulate Hookipa Pharma Longeveron Lipocine GeoVax Labs Lexaria Bioscience DURECT Leap Therapeutics Cocrystal Pharma ProMIS Neurosciences Xenetic Biosciences (NASDAQ:XBIO) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of XBIO or CING? 15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 14.7% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor XBIO or CING? Xenetic Biosciences received 161 more outperform votes than Cingulate when rated by MarketBeat users. However, 76.47% of users gave Cingulate an outperform vote while only 66.92% of users gave Xenetic Biosciences an outperform vote. CompanyUnderperformOutperformXenetic BiosciencesOutperform Votes17466.92% Underperform Votes8633.08% CingulateOutperform Votes1376.47% Underperform Votes423.53% Which has more volatility & risk, XBIO or CING? Xenetic Biosciences has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the S&P 500. Which has higher earnings and valuation, XBIO or CING? Xenetic Biosciences has higher revenue and earnings than Cingulate. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.58M1.86-$4.14M-$2.38-1.31CingulateN/AN/A-$23.53M-$8.48-0.50 Does the media prefer XBIO or CING? In the previous week, Cingulate had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.87 beat Cingulate's score of 0.44 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Overall Sentiment Xenetic Biosciences Very Positive Cingulate Neutral Is XBIO or CING more profitable? Cingulate has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -161.63%. Xenetic Biosciences' return on equity of -49.51% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-161.63% -49.51% -43.99% Cingulate N/A -570.20%-236.15% Do analysts rate XBIO or CING? Cingulate has a consensus target price of $26.00, suggesting a potential upside of 519.05%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryXenetic Biosciences beats Cingulate on 9 of the 17 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.80M$6.88B$5.57B$8.51BDividend YieldN/A2.49%5.27%4.16%P/E Ratio-1.178.4626.7519.65Price / Sales1.86262.48404.17152.19Price / CashN/A65.8538.2534.64Price / Book0.496.526.964.59Net Income-$4.14M$143.26M$3.23B$248.23M7 Day Performance1.14%-0.21%-1.23%-1.07%1 Month Performance3.32%10.62%6.34%2.59%1 Year Performance-19.43%3.63%33.04%13.50% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.9667 of 5 stars$3.11-4.0%N/A-19.2%$4.80M$2.58M-1.174Positive NewsGap DownCINGCingulate2.1 of 5 stars$4.54+4.1%$26.00+472.7%+535.3%$19.28MN/A-0.5420Short Interest ↑Gap DownHOOKHookipa Pharma3.1433 of 5 stars$1.53-1.9%$4.50+194.1%-80.9%$18.65M$9.35M-0.4156LGVNLongeveron3.4977 of 5 stars$1.27+3.3%$8.67+582.4%-59.2%$18.36M$2.23M-0.2020Gap UpLPCNLipocine2.1477 of 5 stars$3.37+6.3%$9.00+167.1%-67.1%$18.03M$3.67M-4.4310News CoverageAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeGOVXGeoVax Labs3.3788 of 5 stars$1.18+5.4%$11.10+840.7%-14.2%$17.93M$5.59M-0.3210News CoverageGap DownHigh Trading VolumeLEXXLexaria Bioscience2.5105 of 5 stars$1.00+1.5%$7.00+600.0%-68.4%$17.56M$525.92K-2.007News CoverageGap UpDRRXDURECT1.3338 of 5 stars$0.55+2.2%N/A-62.7%$17.16M$1.86M-0.9180LPTXLeap Therapeutics2.7039 of 5 stars$0.41+4.5%$4.92+1,097.4%-80.6%$17.02MN/A-0.2140Positive NewsGap DownCOCPCocrystal Pharma2.6215 of 5 stars$1.65+1.2%$7.00+324.2%-35.6%$16.78MN/A-0.8910Short Interest ↑PMNProMIS Neurosciences2.3248 of 5 stars$0.51+5.6%$4.50+791.1%-67.8%$16.51MN/A-5.055Positive News Related Companies and Tools Related Companies CING Competitors HOOK Competitors LGVN Competitors LPCN Competitors GOVX Competitors LEXX Competitors DRRX Competitors LPTX Competitors COCP Competitors PMN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
